The 42nd Annual Symposium on the Biology of the Skin, entitled ''The Genetics of Skin Disease'' , was held in Snowmass Village, Colorado, in July 1993. That meeting presented the opportunity to discuss how modern approaches to molecular genetics and molecular biology could be applied to understanding the mechanisms of skin diseases. The published proceedings of this meeting stated that ''It is an opportune time to examine the genetics of skin disease'' (Norris et al, 1994) . Indeed, this meeting just caught the wave of early pioneering studies that have helped us to understand the molecular basis of a large number of genodermatoses. This overview presented in the 50 th Annual Symposium on the biology of the skin, highlights the progress made in the molecular genetics of heritable skin diseases over the past decade. Key words: Genodermatoses/epidermolysis bullosa/pseudoxanthoma elasticum JID Symposium Proceedings 7: 6^16, 2002 T he recent progress made in molecular genetics of heritable skin diseases is abundantly evident from the present vantage point, as reviewed in the 50th Annual Montagna Symposium on the Biology of Skin, also held in Snowmass Village, Colorado, in July 2001. At the time of our previous meeting, almost a decade ago, the molecular basis of the prototypic genodermatoses, such as epidermolysis bullosa (EB), was beginning to emerge as the ¢rst mutations in the keratin 5 and 14 genes in the simplex forms and in the type VII collagen gene in the dystrophic variants had just appeared in the literature (Epstein, 1992; Fuchs, 1992; Christiano et al, 1993; Hilal et al, 1993) . At the same time, there was very little understanding of the molecular basis of complex multisystem disorders, such as pseudoxanthoma elasticum (PXE), the Ehlers^Danlos syndrome, and the Marfan syndrome. Over the ensuing years, this situation has very quickly changed, and there has been tremendous progress towards understanding the molecular basis of di¡erent forms of single-gene heritable disorders. In fact, mutations have now been identi¢ed in more than 200 distinct genes in a manner that the genetic lesions explain the spectrum of phenotypic manifestations encountered in these diseases ( Table I , Pulkkinen et al, 2002a) .
PREDICTABLE AND SURPRISING CANDIDATE GENES
Examination of the mutation database in these diseases has revealed a number of genes that could have been predicted, on the basis of clinical, histopathologic, immunohistochemical, and/ or ultrastructural analysis, to serve as candidate gene/protein systems. For example, in the case of EB, we initially postulated that mutations in the structural genes expressed within the cutaneous basement membrane zone (BMZ) could harbor mutations that explain the fragility of the skin at the dermal^epidermal junction (Uitto and Christiano, 1992) . This postulate has now been veri¢ed by demonstration of a large number of distinct mutations in as many as 10 di¡erent genes expressed within the cutaneous BMZ (see below). At the same time, a number of mutated genes have turned out to be rather surprising, and the exact relationship of the mutations in the a¡ected genes and their consequences at the clinical and morphologic level are not well understood. An example of such conditions is PXE, in which we and others have recently demonstrated mutations in the ABCC6 gene encoding the MRP6 protein, a putative ATP-dependent transmembrane pump of unknown function (Bergen et al, 2000; Le Saux et al, 2000; Ringpfeil et al, 2000; Struk et al, 2000) . Surprisingly, this gene is expressed primarily, if not exclusively, in the liver and the kidneys, and the pathomechanistic links between the underlying genetic mutations in ABCC6 and calci¢cation of pleiomorphic elastic structures in the skin, the eyes, and the arterial blood vessels remain unclear.
To illustrate the progress made in understanding the genetic basis of heritable skin diseases in general, we will highlight two speci¢c disease entities, in which we have been major contributors, namely epidermolysis bullosa and pseudoxanthoma elasticum.
THE PARADIGM OF EB
An example of the conditions in which spectacular success has recently been made is EB, a heterogeneous group of mechanobullous disorders manifesting with blistering and erosions of the skin (Sybert, 1997; Fine et al, 2000; Bruckner-Tuderman, 2002) . The extent of skin involvement, combined with a number of extracutaneous manifestations encountered in di¡erent variants of EB, can cause considerable morbidity and, in some cases, premature demise of the a¡ected individuals. EB has been traditionally divided into three broad categories based on the level of tissue separation within the cutaneous BMZ: the simplex, junctional, and dystrophic types (Fine et al, 2000) . More recently, we have proposed an additional subgroup, the hemidesmosomal variants of EB, which include generalized atrophic benign EB, EB with pyloric atresia, and EB with muscular dystrophy (Pulkkinen and Uitto, 1998; HERITABLE SKIN DISEASES 9 been identi¢ed in 10 distinct genes expressed at the cutaneous BMZ in di¡erent variants of EB (Pulkkinen and Uitto, 1999) . Examination of the mutation database suggests that the types and combinations of the mutations, their positions along the a¡ected proteins, and the dynamic interplay of the mutant alleles on the individuals' genetic background will determine the continuum of severity in the spectrum of clinical manifestations of EB.
Particularly instructive regarding the progress made in understanding the molecular basis of di¡erent variants of EB and in explaining the clinical spectrum of the disease are the dystrophic forms of EB (DEB). There is considerable genetic and phenotypic variability in DEB. First, the DEB can be inherited in either an autosomal dominant or autosomal recessive fashion. Second, the clinical severity is highly variable demonstrating a spectrum of manifestations. For example, the most severe form of DEB, the Hallopeau^Siemens type, manifests with mutilating scarring with joint contractures, corneal erosions, esophageal strictures, and propensity to formation of cutaneous squamous cell carcinomas that can lead to premature demise of the a¡ected individuals (Fine et al, 2000) . A clinically milder form, the mitis variant of recessive DEB, is characterized by life-long blistering tendency, with limited scarring and less frequent extracutaneous manifestations. In fact, in some cases the clinical severity of mitis recessive DEB can manifest only with subtle nail changes and occasional blistering.
In general, patients with dominantly inherited forms of DEB tend to have a relatively mild phenotype, and they often show blistering only on the hands and feet, and occasionally there is only minimal cutaneous involvement with nail dystrophy. Thus, the dominantly inherited DEB can be indistinguishable from the mitis recessive DEB on clinical, immunohistochemical, and ultrastructural grounds. Speci¢cally, besides the mild clinical features, immunohistochemistry is positive, although occasionally attenuated, for type VII collagen epitopes, and diagnostic transmission electron microscopy usually reveals the presence of some anchoring ¢brils which, however, can be either reduced in number or morphologically altered in both forms of DEB. This situation then poses a diagnostic dilemma concerning the mode of inheritance, de novo dominant vs mitis recessive DEB (Hashimoto et al, 1999) . As discussed below, this dilemma can be resolved by DNA analysis of the mutations in the type VII collagen gene (COL7A1).
Distinct mutations have been disclosed in COL7A1 both in DDEB and RDEB in a large number of families (Table II) . A characteristic genetic lesion in the most severe recessive DEB is premature termination codon-causing mutation, resulting either from a nonsense mutation or from small out-of-frame insertions or deletions or splicing mutations in both COL7A1 alleles. These mutations are distributed along the entire type VII collagen molecule, and most of them are family speci¢c, only a few of them being recurrent (Fig 1) . A characteristic genetic lesion in dominantly inherited forms of DEB is a glycine substitution mutation in one allele of COL7A1 residing within the collagenous domain of the proa1(VII) chain (Fig 1) . The mutated polypeptides are full-length and capable of assembling into triple-helical collagen molecules in combination with wild-type polypeptides ; however, the presence of the glycine substitution destabilizes the collagenous triple-helix, and the presence of the mutated polypeptides causes a dominantly inherited disease through dominant negative interference. Thus, analysis of the type of mutations and their combinations along the type VII collagen gene provides an explanation for the di¡erent modes of inheritance (dominant versus recessive) and the severity of the disease, even though the mutations reside in the same gene (COL7A1) (Pulkkinen and Uitto, 1999) .
THE GENETIC BASIS OF PXE
Another example of a condition in which recent progress has provided understanding of the molecular basis of a genodermatosis is PXE, a systemic heritable connective tissue disorder characterized by progressive calci¢cation of elastic structures in the skin, the eyes, and the cardiovascular system. Certain clinical features, including delayed onset of the clinical manifestations and considerable intra-and interfamilial phenotypic variability, have been puzzling (Neldner, 1988) . Adding to the complexity of PXE is the fact that both autosomal recessive and autosomal dominant inheritance patterns have been reported, and in many cases PXE is sporadic without family history, the precise mode of inheritance thus being unclear (Pope, 1975) . Furthermore, the genetic complexity has been compounded by suggestions that obligate heterozygous carriers in families with autosomal recessive forms of PXE may show minimal manifestations of the disease (Bacchelli et al, 1999; Sherer et al, 2001) . Nevertheless, the involvement of the elastic structures in the skin, the eyes, and the cardiovascular system, and the accumulation of a number of extracellular matrix components, including ¢bronectin and vitronectin as well as various proteoglycan/glycosaminoglycan complexes, in the lesional areas of skin in association with elastic ¢bers, have suggested that PXE is a primary heritable connective tissue disease. In fact, it has been considered as a prototype of such conditions with the primary involvement of elastic ¢bers (McKusick, 1972) . The underlying molecular defect in PXE has remained unknown until recently. Initial observations indicating pathology in the elastic ¢bers suggested that elastin and elastin-associated micro¢brillar proteins could serve as candidate gene/protein systems in PXE. Subsequently, however, the genes encoding elastin as well as elastin-associated proteins, such as ¢brillins 1 and 2 and lysyl oxidase on chromosomes 15 and 5, were excluded by genetic linkage analysis. Subsequent positional cloning approaches allowed mapping of the PXE gene to the short arm of chromosome 16, and the critical interval was further narrowed to B500 kb within the chromosomal region 16p13.1 (Le Saux et al, 1999; Cai et al, 2000) . Examination of the genome database revealed that this region contained four distinct genes with no apparent relation to the extracellular matrix of connective tissue in general or the elastic ¢ber system in particular. Two of the genes, ABCC1 and ABCC6, encode proteins, MRP1 and MRP6, respectively, that are members of the multiple drug resistance-associated protein (MRP) family. Another gene, NPIP, was found to encode the nuclear pore interacting protein, whereas the fourth gene, pM5, encodes a protein with unknown function but shares some similarity with the conserved domain within the collagenase family of proteins.
Sequencing of the four candidate genes within the critical PXE interval resulted in identi¢cation of pathogenetic mutations in the ABCC6 gene, which encodes MRP6, a member of the ATP-dependent membrane transporter family of proteins (Le Saux et al, 2000; Ringpfeil et al, 2000) . Sequence information derived from full-length ABCC6 cDNA predicts that MRP6 has three transmembrane spanning domains and two intracellular nucleotide-binding folds (NBF1 and NBF2) (Fig 2) . The NBF domains contain conserved Walker motifs, critical for ATP binding and for the function of the protein as a transmembrane transporter. Mutation detection strategies have identi¢ed a number of single-base pair substitutions, resulting in missense or nonsense mutations, as well as several small insertions and deletions or Figure 1 . Illustration of the molecular heterogeneity in the dystrophic forms of EB. The structural organization of the type VII collagen a1(VII) polypeptide deduced from the primary nucleotide sequence of full-length cDNA. The polypeptide consists of a collagenous domain that is £anked by Nand C-terminal noncollagenous domains with modular structures, as indicated on the lower left corner. The arrows indicate positions of distinct mutations disclosed in families with dystrophic forms of EB. The mutations depicted above the a1(VII) collagen polypeptide are recessive, and most of them cause premature termination codons, either as a result of nonsense mutations, insertions, or deletions, or as out-of-frame exon skipping mutations, predicting synthesis of a truncated polypeptide or downregulation of the corresponding mRNA transcript through nonsense-mediated mRNA decay. The mutations depicted below the polypeptide are glycine substitution mutations within the collagenous domain. The majority of these missense mutations cause dominantly inherited dystrophic EB through dominant negative interference. (Modi¢ed from Pulkkinen and Uitto, 1999.) large deletions in the ABCC6 gene (Fig 2) . The majority of the mutations reside in the carboxyl-terminal half of the MRP6 polypeptide, a¡ecting critical arginine residues or other conserved amino acids. Furthermore, premature termination codon mutations or large deletions frequently lead to elimination of the third transmembrane domain and the second nucleotidebinding fold. Finally, gene conversion between ABCC6 and one of its pseudogenes has been suggested as a pathogenetic event in some families with PXE (Cai et al, 2001) . The mutations in ABCC6 are present either in a homozygous or in a compound heterozygous state in the a¡ected individuals, whereas heterozygous carriers are clinically una¡ected, consistent with autosomal recessive inheritance pattern. In fact, no molecular evidence for autosomal dominant mode of inheritance has been demonstrated as yet, although some of the heterozygous carriers may demonstrate minimal manifestations of the disease (Sherer et al, 2001) . Also, in some families, the proposed autosomal dominant mode of inheritance could be explained by a pseudodominant family pedigree due to consanguinity in the family (Ringpfeil et al, 2000) .
A surprising ¢nding in the context of clinical manifestations of PXE is the fact that ABCC6/MRP6 is expressed predominantly, if not exclusively, in the liver and the kidneys. The biological function of MRP6 is currently unknown, but there is strong sequence homology with other members of the MRP family, particularly with MRP1, the prototypic protein within the family, which functions as an e¥ux pump for amphipathic and glutathione conjugates. These observations suggest that MRP6 is a metabolic pump expressed in the liver and the kidneys, and PXE could potentially be considered as a metabolic disorder, rather than being a primary connective tissue disease . One could speculate that when MRP6 as a cellular transporter is genetically altered to be nonfunctional, accumulation of yet to be identi¢ed compounds in the circulation could take place. Such compounds could have a⁄nity for elastic ¢bers and calcium and potentially lead to progressive calci¢cation of elastic structures in the a¡ected organs, resulting in progressive degeneration and pathology in the target tissues.
THE IMPACT OF MOLECULAR GENETICS ON PATIENT CARE
The progress made in understanding EB, PXE, and other genodermatoses raises a number of critical questions: What are the bene¢ts of this progress in basic research to the patients and their families? How can we translate this basic information to improved patient care? Is there anything that the practicing Figure 2 . Schematic representation of MRP6, a putative transporter protein, altered by mutations in PXE. As shown, MRP6 consists of three transmembrane domains with ¢ve, six, and six transmembrane spanning segments, respectively. The protein is predicted to have two intracellular nucleotide binding folds (NBF1 and NBF2). The repertoire of mutations within MRP6, as recently published (Cai et al, 2001; Le Saux et al, 2001; Meloni et al, 2001; Ringpfeil et al, 2001; ) is illustrated by arrows pointing to the regions a¡ected by mutations. The majority of the mutations replace critical amino acid residues within the intracellular domains of MRP6 or cause premature termination of translation. Note the presence of large deletion mutations depicted on the top of the ¢gure. Two recurrent mutations, R1141X and del exons 23^29, are in bold. EC, extracellular; IC, intracellular.
dermatologist can convey to the bene¢t of the patients concerning their disease and its molecular basis? In other words, what is the impact of molecular genetics on the patient care? Collectively, signi¢cant bene¢ts are already accruing from the basic research on heritable blistering skin diseases, and expansion of the research database will provide additional insights into the clinical perspective of these conditions. For example, the immediate bene¢ts for EB have already materialized through improved, molecularly based diagnosis with re¢ned classi¢cation, which allows better prognostication regarding the severity and the natural progress of the disease. An example is provided by the junctional form of EB (JEB), which has been traditionally divided, on the basis of the clinical outcome, to two broad categories: (i) the Herlitz variant of JEB that is usually lethal during the ¢rst few months of life; and (ii) the non-Herlitz variant that demonstrates persistent blistering tendency throughout the life, without signi¢cantly compromising the overall lifespan. Molecular analysis of the JEB patients' DNA has revealed that those with the Herlitz variant harbor, as a general rule, a premature termination codon mutation, i.e., a gene defect that predicts synthesis of a truncated and nonfunctional polypeptide, in both alleles of any of the three genes encoding laminin 5 subunits (LAMA3, LAMB3, and LAMC2) (Nakano et al, 2000) . In contrast, patients with the non-Herlitz variants harbor frequently a missense mutation, i.e., an amino acid substitution-causing mutation, in one or both alleles of the corresponding genes. Thus, analysis of DNA from a newborn with clinical, histopathologic, and ultrastructural evidence of JEB allows general predictions as to whether the disease is the severe Herlitz (lethal) variant, or whether the individual is expected to have relatively mild non-Herlitz JEB with a normal lifespan (Nakano et al, 2001a) .
Another example of the impact of molecular genetics relates to genetic counseling of families at risk for recurrence of the disease in the same and subsequent generations. An example is provided by a ''sporadic'' patient with relatively mild DEB with no family history of the disease, and speci¢cally, both parents being clinically normal. The disease in the a¡ected individual could result either from a new (de novo) dominant mutation in one allele of the type VII collagen gene, or the disease could be a mild (mitis) recessive DEB due to mutations in both type VII collagen alleles, inherited separately from each parent. These two possibilities are indistinguishable by clinical examination, as well as by histopathologic, immunohistochemical, and ultrastructural analysis (Hashimoto et al, 1999) . This diagnostic dilemma can be solved, however, by analysis of mutations in the DNA from the a¡ected individual and his/ her parents. Speci¢cally, presence of a single mutation in the proband, in the absence of the corresponding mutation in the parents' DNA isolated from peripheral blood, indicates a de novo dominant mutation. In contrast, identi¢cation of two mutant alleles in the proband's DNA and demonstration of their presence in the respective parents signi¢es mitis recessive DEB. The implications are, of course, that the risk of an a¡ected individual in the case of de novo dominant DEB of having an a¡ected child is one in two, or 50%, whereas the risk of the individual with recessive DEB having an a¡ected o¡spring is very low, re£ecting the relatively low carrier frequency of EB (Pfendner et al, 2001) . At the same time, the risk for the parents of the patient with a de novo dominant mutation of having another a¡ected child is relatively low, whereas the risk for the parents of the patient with a recessive DEB having another a¡ected o¡spring is one in four, or 25%.
PRENATAL TESTING, PREIMPLANTATION GENETIC DIAGNOSIS, AND GENE THERAPY
A consequence of the identi¢cation of speci¢c mutations in genodermatoses has been the development of DNA-based prenatal testing for families at risk for recurrence of severe forms of the disease. Such testing can be performed from a chorionic villus sample as early as the tenth week of gestation or from early amniocentesis performed at the twelfth week. In fact, prenatal testing has already been established for EB and is readily available for the severe forms of recessive DEB and for the Herlitz type of JEB during the ¢rst trimester of pregnancy (Christiano et al, 1996 (Christiano et al, , 1997 . Prenatal predictions have also been made in cases with EB with pyloric atresia, a frequently lethal variant of EB (Nakano et al, 2001b) . DNA-based analysis has essentially replaced the previously employed fetal skin biopsy, which is performed late during the second trimester, as a prenatal diagnostic tool for EB. An extension of DNA-based prenatal testing is the development of preimplantation genetic diagnosis (PGD), which is performed in conjunction with in vitro fertilization (McGrath and Handyside, 1998) . In this procedure, the fertilized embryos are allowed to grow in vitro to the eight-cell stage level, at which time one cell is removed for mutation analysis. Subsequently, embryos lacking the mutation are implanted into the uterus to establish pregnancy, as routinely done as part of in vitro fertilization protocol, therefore excluding the recurrence of the disease in the family. Thus, couples with a child previously a¡ected with EB, or any other severe genodermatosis in which the molecular basis is known, can now initiate the next pregnancy by knowing that there are ways to ¢nd out the genotype of the fetus at the early stages of pregnancy through DNA-based prenatal testing or even before the pregnancy is established by applying PGD.
Finally, it is evident that identi¢cation of the underlying molecular defects in genodermatoses is a prerequisite for development of successful therapies in the future. In particular, development of gene therapy approaches requires precise knowledge of the mutations in the a¡ected genes and their consequences at the mRNA and protein levels . Although successful application of gene therapy for treatment of EB may still be several years away, rapid development of new technologies or promising breakthroughs could lead to durable gene therapy for these devastating skin diseases in the future.
FUTURE PROSPECTS: COMPLEX DISORDERS AND GENETIC SUSCEPTIBILITY
As illustrated above, signi¢cant progress has been made towards understanding the molecular basis of a large number of genodermatoses, and in fact, the majority of the single gene disorders may have been mapped to distinct genetic loci and the underlying mutated genes have been identi¢ed. Nevertheless, the molecular basis of a number of Mendelian disorders still awaits clari¢cation, and it is becoming increasingly evident that a number of disorders can be caused by defects in di¡erent genes with resulting phenocopies or closely resembling phenotypes ( Table I ).
An example of such molecular diversity is Vohwinkel's syndrome, characterized by mutilating keratoderma with pseudoainhum, ichthyosiform erythroderma, and deafness. Our original attempts to clarify the genetic basis of Vohwinkel's syndrome in a family with keratoderma and erythroderma resulted in identi¢cation of mutations in the gene encoding loricrin, a corni¢ed envelope protein expressed in the epidermis (Maestrini et al, 1996) . Subsequently, however, examination of families with classic, more complete forms of Vohwinkel's disease manifesting with deafness, led to identi¢cation of mutations in the GJB2 gene encoding connexin 26, a cell^cell communication protein (Maestrini et al, 1999) . As another example, di¡erent variants of X-linked anhidrotic ectodermal dysplasia have been shown to result from mutations, in addition to ED1, in the IKBKG gene that encodes NEMO, a subunit of the IkB kinase complex ( Table I) . At the same time, incontinentia pigmenti, a complex X-linked dominant disorder, is also due to mutations in the IKBKG gene (Berlin et al, 2002) . The dramatic phenotypic di¡erences in X-linked ectodermal dysplasias, either with immunode¢ciency (EDA-ID) or together with osteopetrosis and lymphedema (OL-EDA-ID), and in incontinentia pigmenti can be explained by the consequences of the mutations within the same gene. Speci¢cally, loss of function mutations in IKBKG, which abolish NFkB signaling, result in incontinentia pigmenti (Smahi et al, 2000) . In contrast, mutations which impair but do not abolish the NFkB signaling are associated with EDA variants with immune de¢ciency (Do⁄nger et al, 2001) . Furthermore, EDA variants without immune de¢-ciency, can be caused by mutations in two di¡erent genes. The X-linked variants are due to mutations in the ED1 gene encoding ectodysplacin A, whereas the autosomal variants with essentially identical phenotypes are due to mutations in the ectodysplacin A receptor gene (DL) (Kere et al, 1996; Monreal et al, 1999) . Both of these gene products participate in NFkB signaling. Thus, further expansion of the molecular basis of single gene disorders, with extended mutation databases towards re¢nement of genotype/ phenotype correlations, is still required for understanding of a number of single gene disorders. At the same time, the molecular diagnostics of genodermatoses is expanding to include complex genetic disorders towards identi¢cation of susceptibility genes (Table III) . A prime example of such conditions is psoriasis, which is clearly known to have a genetic contribution with a major susceptibility locus residing on chromosome 6 in association with the HLA locus. In fact, a number of candidate genes have been recently identi¢ed, and evidence in support of certain genes or in favor of exclusion of the corresponding genes is rapidly appearing in the literature (see, for example, Mallon et al, 1999; Chia et al, 2000; O'Brien et al, 2001; Asumalahti et al, 2002) . Further examples of such conditions are autoimmune disorders, such as systemic lupus erythematosus and vitiligo, for which a shared genetic susceptibility locus has been recently linked to chromosome 17p13 (Nath et al, 2001) .
Another example of a relatively common, complex disorder is atopic dermatitis, and the loci in£uencing atopy have been localized to a number of chromosomal regions, including chromosome 5q31. This region includes SPINK5, which has recently been identi¢ed to cause Netherton syndrome, a rare recessive skin disorder in which atopy is a universal component (Chavanas et al, 2000; Sprecher et al, 2001c) . SPINK5 encodes a complex serine protease inhibitor (LEKTI), which is expressed in epithelial and mucosal surfaces as well as in the thymus. A number of coding polymorphisms in the SPINK5 gene have been demonstrated, and it was discovered that Glu420Lys shows signi¢cant association with atopic dermatitis in two independent panels of families (Walley et al, 2001) . These results implicate a previously unrecognized pathway for the manifestations of atopic dermatitis, and they potentially provide means to interfere with the development of this condition by pharmacologic means. Collectively, these developments herald the extension of molecular genetics to more common cutaneous disorders for which the molecular basis and the pathomechanisms will be the subject of intense research over the next decade. Avila et al (1999) 
